Outlook Therapeutics (OTLK) Cash from Operations: 2015-2020
Historic Cash from Operations for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$12.1 million.
- Outlook Therapeutics' Cash from Operations fell 103.25% to -$12.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$31.8 million, marking a year-over-year increase of 1.55%. This contributed to the annual value of -$68.8 million for FY2024, which is 60.08% down from last year.
- Latest data reveals that Outlook Therapeutics reported Cash from Operations of -$12.1 million as of Q3 2020, which was down 102.80% from -$6.0 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Cash from Operations registered a high of $79,854 during Q3 2017, and its lowest value of -$16.0 million during Q2 2016.
- For the 3-year period, Outlook Therapeutics' Cash from Operations averaged around -$8.0 million, with its median value being -$7.4 million (2018).
- Its Cash from Operations has fluctuated over the past 5 years, first soared by 100.77% in 2017, then tumbled by 10,611.91% in 2018.
- Outlook Therapeutics' Cash from Operations (Quarterly) stood at -$5.8 million in 2016, then slumped by 48.43% to -$8.7 million in 2017, then fell by 12.80% to -$9.8 million in 2018, then soared by 31.77% to -$6.7 million in 2019, then tumbled by 103.25% to -$12.1 million in 2020.
- Its Cash from Operations stands at -$12.1 million for Q3 2020, versus -$6.0 million for Q2 2020 and -$7.1 million for Q1 2020.